bluebird CAR T therapy leads to responses in MM study

bluebird bio Inc. (NASDAQ:BLUE) added $8.65 (14%) to $69 in early after-hours trading after it reported interim results from a Phase I study of bb2121 to treat relapsed or refractory multiple myeloma. Among nine evaluable

Read the full 352 word article

User Sign In